4-Isothioureidobutyronitrile

4-Isothioureidobutyronitrile

SCHEMBL851495

N#CCCCSC(=N)N

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Isothioureidobutyronitrile SCHEMBL851612 0.98 CYP1A2 (0.52)
4-Isothioureidobutyronitrile SCHEMBL20607675 0.96 CYP1A2 (0.50)
SCHEMBL859948 0.93 CYP1A2 (0.52)
Hydrochloric Acid SCHEMBL850423 0.91 CYP1A2 (0.50)
SCHEMBL860625 0.91 CYP1A2 (0.50)
Hydrochloric Acid SCHEMBL860518 0.90 ALDH1A1 (0.48)
SCHEMBL851824 0.86
Hydrochloric Acid SCHEMBL849818 0.84
Bromide SCHEMBL8605247 0.84
SCHEMBL26315979 0.77 CYP1A2 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US claimed
US-20250345322-A1 NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AROG PHARMACEUTICALS INC (US) 2025-11-13 US claimed
EP-4551565-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY Zounek, Alex (DE) 2025-05-14 EP claimed
US-20250041294-A1 Synergistic compositions for use in the treatment of cancer SARTAR THERAPEUTICS OY (FI) 2025-02-06 US claimed
US-20240398831-A1 COMPOSITIONS COMPRISING SMALL MOLECULE REGULATORS OF TUMOR IMMUNITY AND METHODS OF USING SAME UNITED STATES GOVERNMENT 2024-12-05 US claimed
EP-4444314-A1 SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER Sartar Therapeutics Oy (FI) 2024-10-16 EP claimed
EP-4424327-A1 METHOD OR AGENT WITH HDAC REGULATOR, FOR TREATMENT OF DIABETES AND COMPLICATIONS Biozipcode, Inc. (JP) 2024-09-04 EP claimed
EP-4412649-A1 COMPOSITIONS COMPRISING SMALL MOLECULE REGULATORS OF TUMOR IMMUNITY AND METHODS OF USING SAME Duke University (US) 2024-08-14 EP claimed
CN-118354773-A Synergistic composition for the treatment of cancer 萨达治疗公司 2024-07-16 CN claimed
US-20240226088-A1 NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AROG PHARMACEUTICALS, INC. 2024-07-11 US claimed
EP-3969050-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS Nuvation Bio Inc. (US) 2022-03-23 EP claimed
EP-2432464-B1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS INNOVATION PHARMACEUTICALS INC (US) 2019-01-09 EP claimed
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US claimed
CN-102438612-B Nitrile derivatives, their pharmaceutical use and compositions CELLCEUTIX CORP. (US) 2016-02-03 CN claimed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US claimed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US claimed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US claimed
EP-2432464-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS Cellceutix Corporation (US) 2012-03-28 EP claimed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US claimed
WO-2010135170-A2 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 WO claimed